Weeks after raising $40M, Celgene-partnered Inhibrx lays groundwork for nearly $75M public debut
Celgene-partnered biotech Inhibrx has had a busy 2019 so far. The La Jolla, California-based company kicked off an early-stage oncology study, partnered with bluebird bio, signed a pact with Italy’s Chiesi Group and secured a $40 million venture capital injection. On Monday, it laid the groundwork for a roughly $75 million IPO.
Inhibrx is developing a plethora of biologics — it has three oncology programs in human clinical trials, a rare disease program, for which it expects to initiate a human study in the third quarter of 2019, as well as two preclinical drugs.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
